Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors - Takeaways - DentalSpire

Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors

  • By

  • Hana Misganaw

  • Mebratu Tamir

  • Yalewayker Tegegne

  • Zufan Yiheyis Abriham

  • Dereje Mengesha Berta

  • Bisrat Birke Teketelew

  • Negesse Cherie

  • Tsedenya Gebeyehu

  • Elias Chane

  • Abiy Ayele Angelo

  • Aberham Abere

  • Abebaw Setegn

  • Tegegne Eshetu

  • January 30, 2026

  • 0 min

Share

  • 1

    Ascaris lumbricoides is a significant public health challenge, particularly affecting school-age children in socioeconomically disadvantaged populations.

  • 2

    Albendazole is the primary anthelminthic used in Ethiopia's mass drug administration campaigns to combat ascariasis among schoolchildren.

  • 3

    Despite extensive deworming efforts, Ethiopia has not achieved the WHO target for STH elimination, partly due to potential drug resistance.

  • 4

    Re-infection with A. lumbricoides can occur as early as two months post-treatment, highlighting the need for improved hygiene practices.

  • 5

    The study aims to evaluate the efficacy of a single dose of Albendazole and identify factors associated with re-infection in schoolchildren.

Original Source(s)

Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors

  • by Hana Misganaw, Mebratu Tamir, Yalewayker Tegegne, Zufan Yiheyis Abriham, Dereje Mengesha Berta, Bisrat Birke Teketelew, Negesse Cherie, Tsedenya Gebeyehu, Elias Chane, Abiy Ayele Angelo, Aberham Abere, Abebaw Setegn, Tegegne Eshetu

  • January 30, 2026

Related Content

Pain With Movement Linked to Poorer Outcomes in TMD

Systematic review identifies key prognostic factors for TMD pain and function but emphasizes low-certainty evidence and need for more rigorous research.

Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest

Management of incidental STIC lesions with and without BRCA mutations: a survey of current clinical practice in Austria, Germany, and Switzerland